Bupron SR (Bupropion Hydrochloride Extended release Tablets) used

Bupron SR (Bupropion Hydrochloride Extended release Tablets) (a generic product for Wellbutrin) are used to treat major depressive disorder (MDD) to relieve symptoms including severely depressed mood, loss of interest or pleasure in usual activities, feelings of guilt or worthlessness amongst other mood disorders associated with major depression. Bupron SR (Bupropion Hydrochloride Extended release Tablets) are also used to treat nicotine dependence, as part of a smoking cessation programme that includes motivational support, and helps people who are addicted to nicotine to stop smoking, by reducing cravings and the urge to smoke as well as counteracting withdrawal symptoms, like irritability, restlessness and anxiety.

Bupron SR (Bupropion Hydrochloride Extended release Tablets) work

Bupron SR (Bupropion Hydrochloride Extended release Tablets) contain bupropion which is an antidepressant that is chemically unrelated to other known antidepressant agents, although it works at the level of the brain in a way similar to the class of antidepressants known as selective serotonin reuptake inhibitors (SSRI), which block the uptake by nerve cells of serotonin (a neurotransmitter or brain chemical that allows nerve cells to communicate). Bupropion in Bupron SR (Bupropion Hydrochloride Extended release Tablets) has minimal effect on the re-uptake of serotonin, although it is a selective inhibitor of the neuronal re-uptake of other neurotransmitters, in particular the catecholamines noradrenaline and dopamine. Symptoms of depression are thought to be caused by an imbalance of certain neurotransmitters and Bupron SR (Bupropion Hydrochloride Extended release Tablets) help restore the balance of noradrenaline and dopamine in the brain, by blocking the re-uptake of noradrenaline and dopamine, increasing their levels in the brain. The anti-addictive and antidepressive properties of bupropion in Bupron SR (Bupropion Hydrochloride Extended release Tablets) are thought to be due to the same mechanism, as lack of noradrenaline and dopamine may be involved in the addiction process and may contribute to withdrawal symptoms. However, other mechanism may also be involved in helping with smoking cessation, including stimulation by bupropion of noradrenaline and dopamine receptors, increasing the effectiveness of these neurotransmitters, while at the same time blocking the action of nicotine on nicotinic acetylcholine receptor function, resulting in a reduction in the rewarding effects of nicotine, which is what contributes to nicotine addiction.